These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 28122959)

  • 1. Type I interferon-mediated autoimmune diseases: pathogenesis, diagnosis and targeted therapy.
    Psarras A; Emery P; Vital EM
    Rheumatology (Oxford); 2017 Oct; 56(10):1662-1675. PubMed ID: 28122959
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Signaling Pathways of Type I and Type III Interferons and Targeted Therapies in Systemic Lupus Erythematosus.
    Chyuan IT; Tzeng HT; Chen JY
    Cells; 2019 Aug; 8(9):. PubMed ID: 31450787
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Type I Interferons in the Pathogenesis and Treatment of Autoimmune Diseases.
    Jiang J; Zhao M; Chang C; Wu H; Lu Q
    Clin Rev Allergy Immunol; 2020 Oct; 59(2):248-272. PubMed ID: 32557263
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of Long Interspersed Nuclear Element 1 Retroelements and Induction of Type I Interferon in Patients With Systemic Autoimmune Disease.
    Mavragani CP; Sagalovskiy I; Guo Q; Nezos A; Kapsogeorgou EK; Lu P; Liang Zhou J; Kirou KA; Seshan SV; Moutsopoulos HM; Crow MK
    Arthritis Rheumatol; 2016 Nov; 68(11):2686-2696. PubMed ID: 27338297
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Type I interferon signature in systemic lupus erythematosus.
    Bezalel S; Guri KM; Elbirt D; Asher I; Sthoeger ZM
    Isr Med Assoc J; 2014 Apr; 16(4):246-9. PubMed ID: 24834763
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Coordination of retrotransposons and type I interferon with distinct interferon pathways in dermatomyositis, systemic lupus erythematosus and autoimmune blistering disease.
    Kuriyama Y; Shimizu A; Kanai S; Oikawa D; Motegi SI; Tokunaga F; Ishikawa O
    Sci Rep; 2021 Nov; 11(1):23146. PubMed ID: 34848794
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cause and consequences of the activated type I interferon system in SLE.
    Eloranta ML; Rönnblom L
    J Mol Med (Berl); 2016 Oct; 94(10):1103-1110. PubMed ID: 27094810
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The important roles of type I interferon and interferon-inducible genes in systemic lupus erythematosus.
    Luo S; Wang Y; Zhao M; Lu Q
    Int Immunopharmacol; 2016 Nov; 40():542-549. PubMed ID: 27769023
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Type I interferon as a target of treatment in SLE.
    Lee PY; Reeves WH
    Endocr Metab Immune Disord Drug Targets; 2006 Dec; 6(4):323-30. PubMed ID: 17214578
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The importance of the type I interferon system in autoimmunity.
    Rönnblom L
    Clin Exp Rheumatol; 2016; 34(4 Suppl 98):21-4. PubMed ID: 27586799
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The type I interferon system in the development of lupus.
    Rönnblom L; Alm GV; Eloranta ML
    Semin Immunol; 2011 Apr; 23(2):113-21. PubMed ID: 21292501
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Pathogenesis, Molecular Mechanisms, and Therapeutic Potential of the Interferon Pathway in Systemic Lupus Erythematosus and Other Autoimmune Diseases.
    Ramaswamy M; Tummala R; Streicher K; Nogueira da Costa A; Brohawn PZ
    Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681945
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Type I interferon antagonists in clinical development for lupus.
    Paredes JL; Niewold TB
    Expert Opin Investig Drugs; 2020 Sep; 29(9):1025-1041. PubMed ID: 32700979
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interferon lambda in inflammation and autoimmune rheumatic diseases.
    Goel RR; Kotenko SV; Kaplan MJ
    Nat Rev Rheumatol; 2021 Jun; 17(6):349-362. PubMed ID: 33907323
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Type I interferons in systemic autoimmunity.
    Sozzani S; Bosisio D; Scarsi M; Tincani A
    Autoimmunity; 2010 Apr; 43(3):196-203. PubMed ID: 20298124
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of type I interferon-inducible mRNAs as pharmacodynamic markers and potential diagnostic markers in trials with sifalimumab, an anti-IFNα antibody, in systemic lupus erythematosus.
    Yao Y; Higgs BW; Richman L; White B; Jallal B
    Arthritis Res Ther; 2010; 12 Suppl 1(Suppl 1):S6. PubMed ID: 20392292
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytokines as Biomarkers in Systemic Lupus Erythematosus: Value for Diagnosis and Drug Therapy.
    Idborg H; Oke V
    Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34768756
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Type I interferon therapy and its role in autoimmunity.
    Biggioggero M; Gabbriellini L; Meroni PL
    Autoimmunity; 2010 Apr; 43(3):248-54. PubMed ID: 20298125
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The innate immune system in SLE: type I interferons and dendritic cells.
    Rönnblom L; Pascual V
    Lupus; 2008 May; 17(5):394-9. PubMed ID: 18490415
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Type I interferon in systemic lupus erythematosus.
    Crow MK
    Curr Top Microbiol Immunol; 2007; 316():359-86. PubMed ID: 17969456
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.